Healthpeak Properties, Inc. (DOC)
Healthpeak (DOC) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Healthpeak (DOC) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Healthpeak (DOC) Beats Q3 FFO and Revenue Estimates
Healthpeak (DOC) came out with quarterly funds from operations (FFO) of $0.46 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to FFO of $0.45 per share a year ago.
Healthpeak Properties: Attractive Monthly Dividend From A Healthcare REIT Ready To Recover
Healthpeak Properties is a diversified healthcare REIT with a strong tenant mix, robust financials, and a 6.3% monthly dividend yield. DOC benefits from merger synergies, AFFO per share growth, and decent balance sheet management, positioning it well for an improving macro environment. Rate cuts and lower treasury yields are key near-term catalysts, while fundamentals support DOC for further dividend increases.
Healthpeak Properties: A Lot Of Value To Unlock For Investors With A Long-Term Horizon
I'm expanding my portfolio with undervalued REITs like Healthpeak Properties, aiming to capitalize on market overreactions and irrational selling. Healthpeak's valuation is disconnected from its fundamentals; current market pessimism doesn't reflect the cyclical nature of real estate supply and demand. Healthpeak's disciplined capital allocation, including selective buybacks and reinvestment, reflects prudent management in a volatile rate environment.
Healthpeak Properties: Tremendous Value But Catalyst Out Of Sight
Healthpeak Properties trades at a deep discount, with limited downside risk and a well-covered 6.9% dividend yield. The balance sheet is strong, with net debt/EBITDAre at 5.2x and $2.3 billion in liquidity. Valuation is driven by lab space concerns, despite lab space being only 40% of its portfolio, whereas its medical office and senior housing segments remain stable.
Healthpeak Properties, Inc. (DOC) Q2 2025 Earnings Call Transcript
Healthpeak Properties, Inc. (NYSE:DOC ) Q2 2025 Earnings Conference Call July 25, 2025 10:00 AM ET Company Participants Andrew Johns - Senior Vice President of Investor Relations Kelvin O. Moses - Chief Financial Officer Mark Theine - Corporate Participant Scott M.
Healthpeak Q2 FFO Meets Estimates, Same-Store NOI Rises Y/Y
DOC's second-quarter results reflect the continued strong performance of its high-quality lab, outpatient medical and CCRC portfolios.
Healthpeak (DOC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Healthpeak (DOC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Healthpeak (DOC) Q2 FFO Meet Estimates
Healthpeak (DOC) came out with quarterly funds from operations (FFO) of $0.46 per share, in line with the Zacks Consensus Estimate . This compares to FFO of $0.45 per share a year ago.
What's in the Cards for Healthpeak Properties This Earnings Season?
DOC's Q2 earnings are likely to benefit from rising healthcare spending and the aging population. However, higher interest expenses may have hurt it.
Healthpeak (DOC) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Healthpeak (DOC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Healthpeak's Valuation Disconnect: Strong Assets, Low Expectations
Healthpeak Properties is strategically focused on Class A outpatient and life science real estate, benefiting from demographic tailwinds and supply constraints in key markets. The recent Physicians Realty Trust merger enhances scale, operational synergies, and defensibility, positioning Healthpeak for steady FFO growth as sector fundamentals improve. Despite high leverage and capital allocation risks, Healthpeak trades at a significant discount to historical valuation multiples, offering attractive long-term total return potential.
